RIGHT Choice: ribociclib + ET vs combo chemo in aggressive HR+/HER2− advanced breast cancer

Stephanie Graff, MD, Lifespan Cancer Institute and Brown University, Providence, RI, provides an overview of the Phase II RIGHT Choice (NCT03839823) study randomizing patients with high-risk, metastatic HR-posiitve breast cancer to receive either ribociclib plus goserelin acetate with hormonal therapy versus combination chemotherapy. Patient had either visceral crisis, high-burden visceral disease, or rapidly progressive breast cancer. The primary endpoint was progression-free survival (PFS). Median PFS was 24 months with ribociclib plus goserelin acetate with hormonal therapy versus 12 months with chemotherapy. Time to response was slightly faster with chemotherapy. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.